Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry (original) (raw)

Nature volume 446, pages 801–805 (2007)Cite this article

This article has been updated

Abstract

Hepatitis C virus (HCV) is a leading cause of cirrhosis and liver cancer worldwide. A better understanding of the viral life cycle, including the mechanisms of entry into host cells, is needed to identify novel therapeutic targets. Although HCV entry requires the CD81 co-receptor, and other host molecules have been implicated, at least one factor critical to this process remains unknown (reviewed in refs 1–3). Using an iterative expression cloning approach we identified claudin-1 (CLDN1), a tight junction component that is highly expressed in the liver4, as essential for HCV entry. CLDN1 is required for HCV infection of human hepatoma cell lines and is the first factor to confer susceptibility to HCV when ectopically expressed in non-hepatic cells. Discrete residues within the first extracellular loop (EL1) of CLDN1, but not protein interaction motifs in intracellular domains, are critical for HCV entry. Moreover, antibodies directed against an epitope inserted in the CLDN1 EL1 block HCV infection. The kinetics of this inhibition indicate that CLDN1 acts late in the entry process, after virus binding and interaction with the HCV co-receptor CD81. With CLDN1 we have identified a novel key factor for HCV entry and a new target for antiviral drug development.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Change history

In the AOP version of this Letter, the label 'K48V' in Fig. 4h should have read 'K48E'. This figure has now been corrected for both print and online publication on 12 April 2007. The mistake did not affect any results.

References

  1. Bartosch, B. & Cosset, F. L. Cell entry of hepatitis C virus. Virology 348, 1–12 (2006)
    Article CAS Google Scholar
  2. Cocquerel, L., Voisset, C. & Dubuisson, J. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol. 87, 1075–1084 (2006)
    Article CAS Google Scholar
  3. Barth, H., Liang, T. J. & Baumert, T. F. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44, 527–535 (2006)
    Article CAS Google Scholar
  4. Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K. & Tsukita, S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 141, 1539–1550 (1998)
    Article CAS Google Scholar
  5. Hsu, M. et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100, 7271–7276 (2003)
    Article ADS CAS Google Scholar
  6. Bartosch, B. et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278, 41624–41630 (2003)
    Article CAS Google Scholar
  7. Meertens, L., Bertaux, C. & Dragic, T. Hepatitis C Virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J. Virol. 80, 11571–11578 (2006)
    Article CAS Google Scholar
  8. Blanchard, E. et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 80, 6964–6972 (2006)
    Article CAS Google Scholar
  9. Tscherne, D. M. et al. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 80, 1734–1741 (2006)
    Article CAS Google Scholar
  10. Koutsoudakis, G. et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80, 5308–5320 (2006)
    Article CAS Google Scholar
  11. Blight, K. J., McKeating, J. A. & Rice, C. M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76, 13001–13014 (2002)
    Article CAS Google Scholar
  12. Van Itallie, C. M. & Anderson, J. M. Claudins and epithelial paracellular transport. Annu. Rev. Physiol. 68, 403–429 (2006)
    Article CAS Google Scholar
  13. Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623–626 (2005)
    Article ADS CAS Google Scholar
  14. Kato, T. et al. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J. Virol. 79, 592–596 (2005)
    Article CAS Google Scholar
  15. Zhang, J. et al. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 78, 1448–1455 (2004)
    Article CAS Google Scholar
  16. McKeating, J. A. et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J. Virol. 78, 8496–8505 (2004)
    Article CAS Google Scholar
  17. Cormier, E. G. et al. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl Acad. Sci. USA 101, 7270–7274 (2004)
    Article ADS CAS Google Scholar
  18. Heiskala, M., Peterson, P. A. & Yang, Y. The roles of claudin superfamily proteins in paracellular transport. Traffic 2, 93–98 (2001)
    Article CAS Google Scholar
  19. Wu, L. et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384, 179–183 (1996)
    Article ADS CAS Google Scholar
  20. Tiwari-Woodruff, S. K. et al. OSP/claudin-11 forms a complex with a novel member of the tetraspanin super family and β1 integrin and regulates proliferation and migration of oligodendrocytes. J. Cell Biol. 153, 295–305 (2001)
    Article CAS Google Scholar
  21. Furuse, M. et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell Biol. 156, 1099–1111 (2002)
    Article CAS Google Scholar
  22. Barton, E. S. et al. Junction adhesion molecule is a receptor for reovirus. Cell 104, 441–451 (2001)
    Article CAS Google Scholar
  23. Bergelson, J. M. et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320–1323 (1997)
    Article CAS Google Scholar
  24. Coyne, C. B. & Bergelson, J. M. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124, 119–131 (2006)
    Article CAS Google Scholar
  25. Borlak, J., Meier, T., Halter, R., Spanel, R. & Spanel-Borowski, K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 24, 1809–1819 (2005)
    Article CAS Google Scholar
  26. Swisshelm, K., Macek, R. & Kubbies, M. Role of claudins in tumorigenesis. Adv. Drug Deliv. Rev. 57, 919–928 (2005)
    Article CAS Google Scholar
  27. Dhawan, P. et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J. Clin. Invest. 115, 1765–1776 (2005)
    Article CAS Google Scholar
  28. Doughty, A. L., Spencer, J. D., Cossart, Y. E. & McCaughan, G. W. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl. Surg. 4, 15–21 (1998)
    Article CAS Google Scholar
  29. Schluger, L. K. et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 23, 971–976 (1996)
    Article CAS Google Scholar

Download references

Acknowledgements

The authors thank J. Tassello, M. Hunter and N. Torres for excellent technical assistance; S. You for providing HCVcc/Rluc virus stocks; D. Schmid and M. Landthaler for expert advice on RNAi; and M. MacDonald and L. Dustin for reviewing the manuscript. This work was supported by the Greenberg Medical Research Institute, the Ellison Medical Foundation, the Starr Foundation, the Ronald A. Shellow Memorial Fund, the Richard Salomon Family Foundation, and the National Institutes of Health (grants to M.J.E., T.v.H., D.M.T., A.J.S., P.D.B. and C.M.R.). P.D.B. is an Elizabeth Glaser Pediatric AIDS Foundation Scientist. C.M.R. is an Ellison Medical Foundation Senior Scholar in Global Infectious Diseases. T.v.H. and B.W. were supported by postdoctoral fellowships from the Deutsche Forschungsgemeinschaft. This work was presented in part at the 13th International Meeting on Hepatitis C Virus & Related Viruses, Cairns, Australia, 27–31 August, 2006.

Author Contributions M.E., T.v.H. and C.M.R. designed the project, analysed results and wrote the manuscript. M.E., T.v.H., D.M.T., A.J.S., M.P. and B.W. performed the experimental work. T.H. and P.D.B developed the screening technology and assisted in its implementation. T.v.H. and J.A.M were involved in preliminary experiments identifying and characterizing HCV nonpermissive cell lines.

Author information

Author notes

  1. Jane A. McKeating
    Present address: Present address: Division of Immunity and Infection, Institute of Biomedical Research, Medical School, University of Birmingham, Birmingham B15 2TT, UK.,
  2. Matthew J. Evans and Thomas von Hahn: These authors contributed equally to this work.

Authors and Affiliations

  1. Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Ave, New York 10021, USA,
    Matthew J. Evans, Thomas von Hahn, Donna M. Tscherne, Andrew J. Syder, Maryline Panis, Benno Wölk, Jane A. McKeating & Charles M. Rice
  2. Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, New York 10016, USA,
    Theodora Hatziioannou & Paul D. Bieniasz

Authors

  1. Matthew J. Evans
    You can also search for this author inPubMed Google Scholar
  2. Thomas von Hahn
    You can also search for this author inPubMed Google Scholar
  3. Donna M. Tscherne
    You can also search for this author inPubMed Google Scholar
  4. Andrew J. Syder
    You can also search for this author inPubMed Google Scholar
  5. Maryline Panis
    You can also search for this author inPubMed Google Scholar
  6. Benno Wölk
    You can also search for this author inPubMed Google Scholar
  7. Theodora Hatziioannou
    You can also search for this author inPubMed Google Scholar
  8. Jane A. McKeating
    You can also search for this author inPubMed Google Scholar
  9. Paul D. Bieniasz
    You can also search for this author inPubMed Google Scholar
  10. Charles M. Rice
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toCharles M. Rice.

Ethics declarations

Competing interests

The authors declare the following conflicts of interest, which are managed under University policy: C.M.R. has equity in Apath, LLC, which holds commercial licenses for the Huh-7.5 cell line and the HCVcc cell culture system; Rockefeller University has filed a patent on commercial applications of the claudin-I HCV entry factor (inventors M.J.E., T.v.H. and C.M.R.)

Supplementary information

Supplementary Methods and Notes

This file contains Supplementary Methods and Notes with a more in-depth description of the methods and materials employed in this study, additional references and Supplementary Figures 1-8 with Legends. The Supplementary Figures provide additional information on the screening approach that led to the identification of CLDN1 as an HCV co-receptor. They also show more data to support its essential role at the post-binding stage of the HCV entry process. (PDF 4523 kb)

Rights and permissions

About this article

Cite this article

Evans, M., von Hahn, T., Tscherne, D. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.Nature 446, 801–805 (2007). https://doi.org/10.1038/nature05654

Download citation

This article is cited by

Editorial Summary

Hepatitis C co-factor

Claudin-1, a tight junction protein expressed in human liver, has been identified as an essential entry co-factor for hepatitis C virus. Like the CD81 co-receptor, claudin-1 spans the cell membrane four times with two extracellular loops. It functions in the hepatitis C virus entry process at a post-binding and pre-fusion step. This discovery provides insights into the mechanism of viral entry into liver cells, and a potential new target for antiviral drugs.

Associated content